This presentation provides an overview of Oncolytics Biotech and their lead product REOLYSIN®, a therapeutic reovirus being studied for various cancer indications. Key points include: - REOLYSIN® has shown selective cytotoxicity against cancer cells with Ras pathway activation and is currently in six phase II randomized clinical trials in cancers like breast, lung, colorectal, prostate, pancreatic, and ovarian. - Early clinical data shows REOLYSIN® may have immune-mediated anti-tumor activity in addition to direct cytotoxic effects. Combinations with immunotherapy agents are being explored. - Over 1,000 patients have been treated with REOLYSIN® which has shown a good safety profile with mostly

1. Investor Presentation
August 17, 2014

2. Forward Looking Statements
This presentation contains certain forward looking statements relating to the
company’s financial results, business prospects and the development and
commercialization of REOLYSIN®, a therapeutic reovirus. These statements are
based on management’s current expectations and beliefs and are subject to a
number of factors which involve known and unknown risks, delays, uncertainties
and other factors not under the company’s control which may cause actual results,
performance or achievements of the company to be materially different from the
results, performance or other expectations implied by these forward looking
statements.
In any forward looking statement in which Oncolytics Biotech® Inc. expresses an
expectation or belief as to future results, such expectations or beliefs are expressed
in good faith and are believed to have a reasonable basis, but there can be no
assurance that the statement or expectation or belief will be achieved. These
factors include results of current or pending clinical trials, risks associated with
intellectual property protection, financial projections, market projections, actions
by the FDA/HPB/MHRA and those other factors detailed in the company’s filings
with SEDAR and the Securities and Exchange Commission. Oncolytics does not
undertake an obligation to update the forward looking statements, except as
required by applicable laws.
2

3. Oncolytics Overview
o Expanding Clinical Program
o Lead product is REOLYSIN®, a broadly active novel cancer
therapy
o Ongoing clinical trials include six randomized studies:
o Phase II studies ongoing in the US and Canada – breast,
non‐small cell lung, colorectal, prostate, pancreatic and
ovarian cancers
o Strong Intellectual Property Portfolio
o More than 370 patents issued worldwide (27 of which were
issued on or after July 1, 2013)
o Manufacturing at Commercial Scale
o 100L cGMP completed, commercial manufacturing
agreement in place
3

4. REOLYSIN®: An Overview
o REOLYSIN® is a proprietary isolate of the reovirus
o Reovirus is considered safe to humans
o REOLYSIN® has been safely administered to patients via
intravenous, intratumoral and intrathecal injection
o Mechanism of Action (MoA):
o Primary MoA is as a selective cytotoxin, where selectivity is
based on whether cancer cells have constituative Ras
pathway activation; susceptible cancer cells therefore
include those with either:
o EGFR overexpression or mutation; or
o Ras mutation, which includes Kras mutation
o Secondary MoAs may include interferon up regulation in
target tissues, and tumour directed immune response
4

5. Market for Ras Pathway Mediated Cancers
o Estimated global cancer market was US$85 billion in 2013;
this is expected to rise to US$109 billion in 2018
o At least five million new patients per year are expected to
develop cancers with a Ras pathway involvement
o In the developed world alone, at least 2.6 million patients per
year die of cancers that have metastasized
5

6. REOLYSIN®: Clinical History
o To date, over 1,000 patients have been treated
with REOLYSIN®
o Over 30 ongoing and completed studies of
REOLYSIN® in North America and Europe
examining a variety of:
o Modes of administration
o Therapeutic combinations
o Cancer indications and patient populations
o Ongoing preclinical research to bolster clinical
program strategy, trial design, intellectual
property portfolio and regulatory submissions
6

7. Registration Pathway for REOLYSIN®
1) Studies where REOLYSIN® therapy will be used
before standard efficacy‐based therapies (surgery,
radical radiotherapy and chemotherapy) in order to
reduce tumour burden
2) Studies based on progression‐free survival
endpoints (EU) and overall survival endpoints (US)
of REOLYSIN® in combination with chemotherapy
and/or radiotherapy
3) Studies based on exploiting secondary immune
based MoA
7

8. Registration Pathway
for REOLYSIN® (I)

9. REO 013: REOLYSIN® Intravenous
Monotherapy Metastatic Liver Lesion
o Image shows positive (red
staining) for reovirus in
the metastatic lesions
(blue arrow) and negative
for reovirus in the normal
cells (red arrow)
o Nine out of ten patients
showed the same pattern,
i.e. targeted delivery to
metastatic tumor lesions
of the liver
9

10. REO 018 Head and Neck Cancer: Randomized
Tumor Specific Response Data
Two endpoints:
o The first endpoint examined initial percentage tumor changes between
baseline and first post treatment scans in all patients, differentiating
between loco‐regional tumours and metastatic tumours
o This is a measure of rate or velocity of response, not magnitude of response
o Of the total 105 patients with evaluable metastatic tumors, 86% (n=50) of
those in the test, and 67% (n=55) in the control arm, arm had tumor
stabilization (0% growth) or shrinkage
o This is a statistically significant difference, with a p‐value of 0.025
o The second endpoint compared percentage tumour shrinkage at the same
time points
o Patients with loco‐regional disease with or without distal metastases on the
test arm had a decrease in tumor volume of an average of 23% over control
(p=0.076, n = 118)
o Patients with distal metastases only on the test arm had a decrease in tumor
volume of an average of 30% over control (p=0.021, n=47)
10

11. REO 011: Head & Neck Cancer Patient
with Partial Response in Liver Metastases
Prior treatment: radiation
Response maintained through 8 cycles
Pre‐Treatment Post‐Cycle 6
11

12. Registration Pathway
for REOLYSIN® (II)

13. REO 018 Head and Neck Cancer: Top‐
Line Efficacy Data
o Data announced November 21, 2013 and April 8, 2014
o Patients with loco‐regional disease with or without distal metastases in
the test arm (n=62) showed a median PFS of 94 days (13.4 weeks), versus
50 days (7.1 weeks) in the control arm (n=56)
o Patients who received REOLYSIN® demonstrated increased benefit through
five cycles of therapy
o An intent‐to‐treat analysis of the 118 loco‐regional patients using Type II
censoring from the median PFS of each arm showed a statistically
significant improvement in PFS of the test arm versus that of the control
arm (p=0.0072, hazard ratio=0.5360)
o An intent‐to‐treat analysis of the 118 loco‐regional patients performed on
all patients to the median PFS in each arm, censoring any patients who
received post‐discontinuation therapy at the date at which they
commenced the first of these therapies showed a statistically significant
improvement in OS of the test arm versus the control arm (p=0.0146,
hazard ratio=0.5099)
13

14. Randomized Clinical Trial Program
for REOLYSIN®: Active Studies
14
Trial Phase Sponsor n Enrollment Status
IND 213: Intravenous REOLYSIN® in Combination with
Paclitaxel in Patients with Advanced or Metastatic Breast
Cancer
II NCIC CTG 100 >50% complete
IND 211: Intravenous REOLYSIN® in Combination with
Docetaxel or Pemetrexed in Patients with Previously‐
Treated Advanced or Metastatic Non‐Small Cell Lung
Cancer (NSCLC)
II NCIC CTG 150 >75% complete
IND 210: Intravenous REOLYSIN® in Combination with
FOLFOX‐6 Plus Bevacizumab (Avastin®) in Patients with
Advanced or Metastatic Colorectal Cancer
II NCIC CTG 100 >90% complete
IND 209: Intravenous REOLYSIN® in Combination with
Docetaxel in Patients with Recurrent or Metastatic
Castration‐Resistant Prostate Cancer
II NCIC CTG 80 >75% complete
OSU‐10045: Intravenous REOLYSIN® in Combination with
Paclitaxel and Carboplatin for Patients with Metastatic
Pancreatic Cancer
II NCI 70 complete
GOG‐0186H: Intravenous REOLYSIN® in Combination with
Paclitaxel for Patients with Persistent or Recurrent Ovarian,
Fallopian Tube or Primary Peritoneal Cancer
II NCI/GOG 110 >95% complete

15. Registration Pathway
for REOLYSIN® (III)

16. Days after REOLYSIN® administration:
0 3 43 88 167 537
(Post Debulking)
REO 003: REOLYSIN® Intratumoural
Monotherapy Anaplastic Astrocytoma
Early Cytotoxic Activity Followed by Late Stage Immune-Mediated
Response Against the Residual Tumour
16

17. Exploiting Immune Based MoA
 Ongoing preclinical research conducted after
immune responses were noted in early
monotherapy studies has led to two clinical
candidate programs:
 GM‐CSF in combination with REOLYSIN®; or
 A checkpoint inhibitor in combination with
REOLYSIN®
17

18. GM‐CSF + REOLYSIN®: Effect on
Overall Survival
18

19. REOLYSIN® and Safety
o More than 1,000 patients treated, more than 900 intravenously at
doses up to 3x1010 TCID50 daily
o No maximum tolerated dose (MTD) reached to date
o Monotherapy toxicities have generally been mild (grade 1 or 2) and
included chills, fever, headache, cough, myalgia, runny nose, sore
throat, fatigue and grade 1 or 2 lymphopenia and neutropenia
o Transient grade 3 and 4 toxicities included lymphopenia and
neutropenia
o These symptoms were more frequently observed from day 2 of
treatment and usually lasted less than 6 hours
19

20. REO 018: Top‐Line Safety Data
o Data announced November 21, 2013 for all 167 patients enrolled
o REOLYSIN® was safe and well‐tolerated by patients
o Patients on the test arm of the study experienced a higher
incidence of flu‐like symptoms consistent with earlier clinical trials
of REOLYSIN® and treatment with a virus
o Most commonly mild fever, chills, nausea and diarrhea
o Fewer patients required dose reductions of paclitaxel due to
neuropathy or neurotoxicity on the test arm than the control arm
(zero in the test arm versus six in the control; p=0.028)
o On this basis, Oncolytics intends to explore the potential
chemoprotective and neuroprotective properties of REOLYSIN® in
future clinical studies
20

21. Intellectual Property
o More than 370 patents issued worldwide, including 56 US
and 20 Canadian
o Reovirus issue patent claims cover:
o Compositions of matter comprising reovirus
o Pharmaceutical use of reoviruses to treat neoplasia and cellular
proliferative diseases
o Combination therapy with radiation, chemotherapy and/or
immune suppressants
o Methods for manufacturing reovirus and screening for
susceptibility to reovirus
o Pharmaceutical use of reoviruses in transplantation procedures
o Approximately 235 pending applications worldwide
21

22. Manufacturing
o Now produced at 100L under cGMP with final formulation
o Commercial manufacturing agreement with SAFC in place
22

23. Market & Capital Data
(all amounts in CAD)
Exchanges NASDAQ:ONCY
TSX:ONC
Shares Outstanding (June 30,
2014)
88,247,844
Price
Options Outstanding (June 30,
2014)
$3.49 (weighted
average)
5,987,844
Fully Diluted (June 30, 2014) 94,235,688
Cash/Cash Equivalents
(June 30, 2014)
$18.9M
23

24. Oncolytics Overview
o Expanding Clinical Program
o Lead product is REOLYSIN®, a broadly active novel cancer
therapy
o Ongoing clinical trials include six randomized studies:
o Phase II studies ongoing in the US and Canada – breast,
non‐small cell lung, colorectal, prostate, pancreatic and
ovarian cancers
o Strong Intellectual Property Portfolio
o More than 370 patents issued worldwide (27 of which were
issued on or after July 1, 2013)
o Manufacturing at Commercial Scale
o 100L cGMP completed, commercial manufacturing
agreement in place
24

25. Investor Presentation
August 17, 2014